<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!--[if IE 6]><html lang="en" id="ie6"><![endif]-->
<!--[if IE 7]><html lang="en" id="ie7"><![endif]-->
<!--[if IE 8]><html lang="en" id="ie8"><![endif]-->
<!--[if IE 9]><html lang="en" id="ie9"><![endif]-->
<!--[if !(IE 6) | !(IE 7) | !(IE 8) | !(IE 9) ]><!-->
<html xmlns="http://www.w3.org/1999/xhtml"  lang="en">
<!--<![endif]-->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no" />
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
<meta name="HandheldFriendly" content="true" />
	<meta property="og:title" content="Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes | Press Release"/>
	<meta property="og:type" content="article"/>
	<meta property="og:url" content=""/>
	<meta property="og:site_name" content="CrashCade | Alternative News | True News| People Powered News"/>
	<meta property="og:description" content="MOUNTAIN VIEW, CA–(Marketwired – October 06, 2014) – VIVUS, Inc. (NASDAQ: VVUS) today announced the publication of a paper examining study results..."/>
	<meta property="fb:app_id" content="1562363863975464"/><link type="text/css" rel="stylesheet" href="/static/css/global-bin-rev-14.css" />
<link type="text/css" rel="stylesheet" href="/static/css/story-bin-rev-14.css" />
<link type="text/css" rel="stylesheet" href="/static/css-dashboard/jquery-ui.css" />
<link type="text/css" rel="stylesheet" href="/static/css/responsive-bin-rev-14.css" />
<script type="text/javascript" src="/static/js/jquery.ui.fancybox.js"></script>
<script type="text/javascript" src="/static/js/responsive-bin-rev-14.js"></script>
<script type="text/javascript" src="/static/js/global-bin-rev-14.js"></script>
<script type="text/javascript" src="/static/js/story-bin-rev-14.js"></script>
<title>Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes | Press Release</title>
</head>
<body>
<div id="fb-root"></div>
<script>(function(d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src = "//connect.facebook.net/en_US/sdk.js#xfbml=1&appId=1562363863975464&version=v2.0";
fjs.parentNode.insertBefore(js, fjs);
}(document, 'script', 'facebook-jssdk'));</script>
<span id="admin_tab"></span>
<div>
<div id="wrapper">
    <div id="header">
        <div id="logo"><a href="/" id="mainlogo"><img src="/img/crashcade/logo.png" alt="logo" border="0" height="40" /></a></div>
        <div id="user_status"><script type="text/javascript">showLogin();</script></div>
    </div>
    <div id="topinfo_wrapper">
        <div id="menu" class="fixed-enabled">
		<div id="menu_center">
			<ul>
               <li><a href="/"><img src="/img/crashcade/home-icon.png" /></a></li>
                <li><a href="/top/featured.html">Featured</a></li>
                <li><a href="/top/news.html">News</a></li>
                <li><a href="/top/entertainment.html">Entertainment</a></li>
                <li><a href="/top/lifestyle.html">Lifestyle</a></li>
                <li><a href="/top/science.html">Science</a></li>
			</ul>
			<div id="searchbar">
                <form action="/googlesearch/" id="cse-search-box">
                    <input type="hidden" name="cx" value="013141870841744815044:i5qb7wmirda" />
                    <input type="hidden" name="cof" value="FORID:10" />
                    <input type="hidden" name="ie" value="UTF-8" />
                    <input type="text" name="q" autocomplete="off" id="q" size="30" />
                    <button type="submit" class="icon-search" name="sa" id="sa" value="" onclick="javascript:if ($('#q').val()=='') { $('#q').focus(); alert('Please, input query text!'); return false; }"></button>
                </form>
           </div>
		</div>
	</div>
	<div class="clear"></div>
	<div id="topstyle_box">
        <div id="topstyle_box_ads">
            <!--/* Top Ad */-->
            <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
            <!-- Crashcade 728x90 -->
            <ins class="adsbygoogle"
                 style="display:inline-block;width:728px;height:90px"
                 data-ad-client="ca-pub-7904820019573435"
                 data-ad-slot="5282300212"></ins>
            <script>
            (adsbygoogle = window.adsbygoogle || []).push({});
            </script>
            <!--/* End Top Ad */-->
        </div>
        <div id="topstyle_box_info">
            <div id="got_a_news_story">
                <div id="submitnews">
                    <div class="uptext">
                        <p>Got a news story? Hot tip?</p>
                        <p>Something that the public needs to know?</p>
                    </div>
                </div>
            </div>
        </div>
	</div>
	<div class="clear"></div>
		<div id="navbar">
	<ul id="breadcrumbs"><li class="crumbs"><a href="/">HOME</a></li>
	<li id="crumbs" class="crumbs"><a href="/press-release">Press Release</a></li>	</ul>
		<div id="edit_delete"></div>
 		<div id="date"></div>
	<script type="text/javascript">showDate();</script>
	</div>
	<div class="clear"></div>
	</div>
<div id="story_wrapper" class="story_wrapper">
<div id="story_column">
<div id="infobar">
<div id="profile_pic"><img id="profile_image" src="/img/bio-placeholder.gif" alt="Profile image" class="" style="margin-top: -5px; "></div>
<div id="profile_info">
<div id="like_contributor"><span id="like_contributor_count"></span></div>
<div id="like_story"><span id="like_story_count"></span></div>
<div id="attribution">By <span id="pen_name" class="authors_name">CDN</span><span id="roles"></span><br /><a id="profile_href" href="/contributor/pages/0/086/bio.html">Contributor profile</a> | <a id="stories_href" href="/contributor/pages/0/086/stories.html">More stories</a><br><div id="subscribenewsletter"></div></div>
</div>
<div id="viewcounters">
<table border="0" cellpadding="0" cellspacing="0" style="width:160px; margin: 0px; padding: 0px; line-height: 12px;">
<tr><td height="8" colspan="2" align="center"><strong>Story Views<br /><br /></strong></td></tr>
<tr><td align="left" width="110">Now:</td><td align="left"><span id="chartbeat_count"></span></td></tr>
<tr><td align="left">Last Hour:</td><td align="left"><span id="counter_hour"></span></td></tr>
<tr><td align="left">Last 24 Hours:</td><td align="left"><span id="counter_day"></span></td></tr>
<tr><td align="left">Total:</td><td align="left"><span id="counter_total"></span></td></tr>
</table>
</div>
<div id="badges"><div id="featured_contributor_story"></div></div>
</div>

<div id="headline"><h1>Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes</h1></div>
<div id="create_date">Monday, October 6, 2014 4:40</div>

<div id="disclaimer"></div>
<div id="story_toolbar">
<div id="fact_meter"><span id="fact_percent"></span>% of readers think this story is Fact.  Add your two cents.<br /><div id="fiction" class="fiction_unselected"></div><div id="scale"></div><div id="fact" class="fact_unselected"></div></div>

<div id="in_line_story_sharing" style="overflow: visible; width: 100%">
<div id="ilss_facebook_like">
	<div class="fb-like" data-layout="button_count" data-action="like" data-show-faces="false" data-share="true"></div>
</div>
<div id="ilss_twitter_share">
	<a href="https://twitter.com/share" class="twitter-share-button" data-url="" data-text="MOUNTAIN VIEW, CA–(Marketwired – October 06, 2014) – VIVUS, Inc. (NASDAQ: VVUS) today..." data-via="CrashCadeNews" data-counturl="http://crashcade.com/press-release/2014/10/newly-published-data-highlight-the-effects-of-weight-loss-with-qsymia-in-type-2-diabetes-386.html">Tweet</a>
</div>
<div id="ilss_google">
	<!-- Place this tag in your head or just before your close body tag. -->
	<script src="https://apis.google.com/js/platform.js" async defer></script>

	<!-- Place this tag where you want the +1 button to render. -->
	<div class="g-plusone" data-size="medium" data-href=""></div>
</div>
<div id="ilss_linkedin">
	<script src="//platform.linkedin.com/in.js" type="text/javascript">lang: en_US</script>
	<script type="IN/Share" data-url="" data-counter="right"></script>
</div>
<div id="ilss_email_share"><span id="email_share_count_top">0</span></div>
</div>
</div>
<input type="hidden" name="author_id" id="author_id" value="86"/>
<input type="hidden" name="story_id" id="story_id" value="386"/>
<input type="hidden" name="category_id" id="category_id" value="29"/>
<div id="contributor_stories"></div>
<!--INFOLINKS_ON-->
<div id="body">
		<div class="nd_single"><div>
<p><span>MOUNTAIN VIEW, CA</span><span>&#8211;(Marketwired &#8211; October 06, 2014) &#8211; </span><a rel="nofollow" target="_blank" href="/r2/?url=http://www.vivus.com" rel="nofollow" target="_blank">VIVUS, Inc.</a> (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="VVUS">VVUS</ticker>) today announced the publication of a paper examining study results that demonstrate the positive impact of weight loss with Qsymia<sup>®</sup> (phentermine and topiramate extended-release) capsules CIV (PHEN/TPM ER) plus lifestyle modification on glycemic control in subjects with type 2 diabetes. </p>
<p>The paper was published <a rel="nofollow" target="_blank" href="/r2/?url=http://care.diabetesjournals.org/content/early/2014/09/19/dc14-0930.full.pdf+html" rel="nofollow" target="_blank">online</a> in the journal <em>Diabetes Care</em>. </p>
<p>Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes or high cholesterol. </p>
<p>The authors examined results from two randomized, 56-week placebo-controlled clinical studies (phase 2 study, OB-202/DM-230, and a <em>post hoc</em> analysis of phase 3 CONQUER study) in overweight or obese patients with type 2 diabetes over a broad range of severity, treated with lifestyle modification and PHEN/TPM ER. The subset of patients with type 2 diabetes in CONQUER was treated with metformin or diet alone at study entry, while patients in OB-202/DM-230 had more longstanding diabetes that required more intensive therapy. </p>
<p>The study groups comprised 130 subjects with type 2 diabetes enrolled in OB-202/DM-230 (mean baseline HbA1c 8.7%) and 388 subjects with type 2 diabetes in CONQUER (mean baseline HbA1c 6.8%). At week 56 in OB-202/DM-230, change in weight (from intent-to-treat sample with last observation carried forward [ITT-LOCF]) was -2.7% for placebo and -9.4% for PHEN/TPM ER top dose (15/92 mg; <em>P</em><0.0001 vs. placebo). Change in HbA1c level (ITT-LOCF) was -1.2% for placebo and -1.6% for PHEN/TPM ER top dose (<em>P</em>=0.0381). In both OB-202/DM-230 and CONQUER, greater numbers of patients randomized to receive PHEN/TPM ER treatment achieved the recommended HbA1c targets, with reduced need for diabetes medications when compared with the placebo group. </p>
<p>Common adverse events included paraesthesia, constipation, and insomnia. </p>
<p>&#8220;These data confirm the efficacy of medically-assisted weight loss in type 2 diabetes patients,&#8221; said Timothy Garvey, MD, Chairman of the Department of Nutrition Sciences, University of Alabama at Birmingham, the lead author and an endocrinologist specializing in metabolic diseases. &#8220;The significant impact on cardiometabolic parameters observed in these studies, particularly with respect to HbA1c lowering, further proves that lifestyle modification combined with a weight loss medication such as PHEN/TPM ER can be considered integral to the treatment of obese and overweight patients with type 2 diabetes.&#8221;</p>
<p align="left"><strong><span style="text-decoration:underline">About the Study<br />
</span></strong><em>Authors: W. Timothy Garvey, Donna H. Ryan, Nancy J.V. Bohannon, Robert F. Kushner, Miriam Rueger, Roman V. Dvorak, and Barbara Troupin<br /> Title: &#8221;Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended-Release&#8221;<br />
</em><a rel="nofollow" target="_blank" href="/r2/?url=http://care.diabetesjournals.org/content/early/2014/09/19/dc14-0930.full.pdf+html" rel="nofollow" target="_blank">DOI: 10.2337/dc14-0930</a>
</p>
<p><strong><span style="text-decoration:underline">About Qsymia<br />
</span></strong>Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. </p>
<p>The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
</p>
<p><strong><span style="text-decoration:underline">Important Safety Information<br />
</span></strong>Qsymia is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia. </p>
<p>Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus. </p>
<p>The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.
</p>
<p><strong><span style="text-decoration:underline">About VIVUS<br />
</span></strong>VIVUS is a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity. For more information about the company, please visit <a rel="nofollow" target="_blank" href="/r2/?url=http://www.vivus.com" rel="nofollow" target="_blank">www.vivus.com</a> </p>
<p>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;forecast,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;opportunity&#8221; and &#8220;should,&#8221; among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS&#8217;s Form 10-K for the year ended December 31, 2013 as filed on February 28, 2014 and as amended by the Form 10-K/A filed on April 30, 2014, and periodic reports filed with the Securities and Exchange Commission.</p>
</div>
<p>]]><![CDATA[</p>
<div class="mw-contact">
<p><strong>VIVUS, Inc.</strong><br />Dana B. Shinbaum<br /> Corporate Development &#038; Investor Relations<br /><a rel="nofollow" href="mailto:shinbaum@vivus.com" rel="nofollow" target="_blank">shinbaum@vivus.com</a><br /> (650) 934-5200</p>
<p>The Trout Group<br /> Brian Korb<br /><a rel="nofollow" href="mailto:bkorb@troutgroup.com" rel="nofollow" target="_blank">bkorb@troutgroup.com</a><br /> (646) 378-2923</p>
</div>
<p>Source: <a href="/r2/?url=http://feeds.mwnewsroom.com/article/rss?id=1883117"> http://feeds.mwnewsroom.com/article/rss?id=1883117</a></p>
<br /><br />Source: <a href="/r2/?url=http://feeds.mwnewsroom.com/article/rss?id=1883117"> http://feeds.mwnewsroom.com/article/rss?id=1883117</a></div></div>
<!--INFOLINKS_OFF-->
<div id="story-pagenavi-bar"></div>
<div style="clear:both"></div>
<div id="story_ad_bottom" style="margin-top:20px;"></div>
<img id="report_abuse" src="/img/report_abuse.png" width="65" height="66" alt="Report abuse" />
<div style="clear:both; padding-top:15px;"></div>

<div class="clear" id="related_stories">Related Stories</div>
<div id="category_stories">

    <ul><li class="related_story"><a href="/press-release/2014/10/loanz-announces-2-million-seed-financing-385.html" title="LOANZ Announces $2 Million Seed Financing"> LOANZ Announces $2 Million Seed Financing</a></li><li class="related_story"><a href="/press-release/2014/10/smarthome-ventures-highlights-focus-on-user-experience-design-mark-rolston-to-serve-as-chief-creative-officer-384.html" title="SmartHome Ventures Highlights Focus on User Experience Design &#8212; Mark Rolston to Serve as Chief Creative Officer"> SmartHome Ventures Highlights Focus on User Experience Design &#8212; Mark Rolston to Serve as Chief Creative Officer</a></li><li class="related_story"><a href="/press-release/2014/10/ready-set-rocket-univision-communications-win-2014-omma-award-for-website-excellence-in-the-business-to-business-category-383.html" title="Ready Set Rocket &#038; Univision Communications Win 2014 Omma Award for Website Excellence in the Business to Business Category"> Ready Set Rocket &#038; Univision Communications Win 2014 Omma Award for Website Excellence in the Business to Business Category</a></li><li class="related_story"><a href="/press-release/2014/10/seaniemac-announces-shareholder-update-382.html" title="SeanieMac Announces Shareholder Update"> SeanieMac Announces Shareholder Update</a></li><li class="related_story"><a href="/press-release/2014/10/hp-to-separate-into-two-new-industry-leading-public-companies-381.html" title="HP to Separate Into Two New Industry-Leading Public Companies"> HP to Separate Into Two New Industry-Leading Public Companies</a></li><li class="related_story"><a href="/press-release/2014/10/cannabis-kinetics-corp-places-first-order-to-import-coco-coir-growing-medium-380.html" title="Cannabis Kinetics Corp. Places First Order to Import Coco Coir Growing Medium"> Cannabis Kinetics Corp. Places First Order to Import Coco Coir Growing Medium</a></li><li class="related_story"><a href="/press-release/2014/10/uboss-and-yealink-enhance-automation-and-customization-for-broadsoft-service-providers-379.html" title="Uboss and Yealink Enhance Automation and Customization for BroadSoft Service Providers"> Uboss and Yealink Enhance Automation and Customization for BroadSoft Service Providers</a></li><li class="related_story"><a href="/press-release/2014/10/digx-loads-high-life-media-inc-with-twice-the-fire-power-378.html" title="DIGX Loads High Life Media Inc. With Twice the Fire Power"> DIGX Loads High Life Media Inc. With Twice the Fire Power</a></li><li class="related_story"><a href="/press-release/2014/10/music-arts-announces-upgrade-your-sound-event-line-up-377.html" title="Music &#038; Arts Announces Upgrade Your Sound Event Line-Up"> Music &#038; Arts Announces Upgrade Your Sound Event Line-Up</a></li><li class="related_story"><a href="/press-release/2014/10/bbs-and-unplugged-performance-release-tesla-model-s-upgraded-wheel-set-376.html" title="BBS and Unplugged Performance Release Tesla Model S Upgraded Wheel Set"> BBS and Unplugged Performance Release Tesla Model S Upgraded Wheel Set</a></li></ul>
</div>

<div id="comments">
<div id="b4in_comments_body"><!-- Jump Link -->
<a id="comments" href="comments" style="visibility:hidden"></a>

<!-- Comments -->
		<div id="respond">
		<h2>Comments</h2>
  		<div class="cancel-comment-reply"><img src="/images/story/cross.png" /> <a rel="nofollow" id="cancel-comment-reply-link" href="/#respond" style="display:none;">Click here to cancel reply.</a></div>
		
  		<form action="/core/ajax/comment/add_comment.php" method="post" id="commentform"> 
        <div class="wpn_comment_heading textarea_heading">Your Comments</div>
    		<div class="wpn_field" style="margin:0;"><textarea name="comment_text" id="comment_text"    rows="10" tabindex="4"></textarea></div>
    		<div class="wpn_comment_submit">
				<img id="comment_submiting" src="/images/misc/loading.gif" width="24" height="24" alt="Processing comment" align="bottom" style="display:none; position: relative; top: 9px;" />
				
				<div id="wp_emoticons" style="float:left">
				<a href="javascript:grin(':?:')" ><img src="/images/smilies/icon_question.gif"  alt="Question   "  title="Question" /></a>
				<a href="javascript:grin(':razz:')" ><img src="/images/smilies/icon_razz.gif"   alt="Razz  "  title="Razz"/></a>
				<a href="javascript:grin(':sad:')"><img src="/images/smilies/icon_sad.gif"  alt="Sad   "  title="Sad" /></a>
				<a href="javascript:grin(':evil:')" ><img src="/images/smilies/icon_evil.gif"   alt="Evil  "  title="Evil"/></a>
				<a href="javascript:grin(':!:')" ><img src="/images/smilies/icon_exclaim.gif"   alt="Exclaim  "  title="Exclaim"/></a>
				<a href="javascript:grin(':smile:')"><img src="/images/smilies/icon_smile.gif"  alt="Smile  "  title="Smile"/></a>
				<a href="javascript:grin(':oops:')" ><img src="/images/smilies/icon_redface.gif"   alt="Redface  "  title="Redface"/></a>
				<a href="javascript:grin(':grin:')" ><img src="/images/smilies/icon_biggrin.gif"   alt="Biggrin  "  title="Biggrin"/></a>
				<a href="javascript:grin(':eek:')"><img src="/images/smilies/icon_surprised.gif"   alt="Surprised  "  title="Surprised"/></a>
				<a href="javascript:grin(':shock:')"><img src="/images/smilies/icon_eek.gif"  alt="Eek   "  title="Eek" /></a>
				<a href="javascript:grin(':???:')"><img src="/images/smilies/icon_confused.gif"  alt="Confused   "  title="Confused" /></a>
				<a href="javascript:grin(':cool:')" ><img src="/images/smilies/icon_cool.gif"   alt="Cool  "  title="Cool"/></a>
				<a href="javascript:grin(':lol:')"><img src="/images/smilies/icon_lol.gif"  alt="LOL   "  title="LOL" /></a>
				<a href="javascript:grin(':mad:')"><img src="/images/smilies/icon_mad.gif"  alt="Mad   "  title="Mad" /></a>
				<a href="javascript:grin(':twisted:')"><img src="/images/smilies/icon_twisted.gif"   alt="Twisted  "  title="Twisted"/></a>
				<a href="javascript:grin(':roll:')" ><img src="/images/smilies/icon_rolleyes.gif"  alt="Rolleyes   "  title="Rolleyes" /></a>
				<a href="javascript:grin(':wink:')" ><img src="/images/smilies/icon_wink.gif"   alt="Wink  "  title="Wink"/></a>
				<a href="javascript:grin(':idea:')" ><img src="/images/smilies/icon_idea.gif"   alt="Idea  "  title="Idea"/></a>
				<a href="javascript:grin(':arrow:')"><img src="/images/smilies/icon_arrow.gif"  alt="Arrow  "  title="Arrow"/></a>
				<a href="javascript:grin(':neutral:')"><img src="/images/smilies/icon_neutral.gif"   alt="Neutral  "  title="Neutral"/></a>
				<a href="javascript:grin(':cry:')"><img src="/images/smilies/icon_cry.gif"  alt="Cry   "  title="Cry" /></a>
				<a href="javascript:grin(':mrgreen:')"><img src="/images/smilies/icon_mrgreen.gif"   alt="Mr. Green  "  title="Mr. Green" /></a>
				</div>
				<input name="submit" type="button" id="comment_submit" tabindex="5" value="Submit" /><input type='hidden' name='comment_post_ID' value='386' id='comment_post_ID' />
<input type='hidden' name='comment_parent' id='comment_parent' value='0' />
</div>
				<input type="hidden" name="comment_category_id" id="comment_category_id" value=""/> 
		
		  	</form>
  
</div>
<br />

<!-- If comments are open, but there are no comments. -->
</div>

</div>
</div>
<div id="tile_column">
<div class="right_stories">
    <h2>Today's Top Stories</h2>
	<span id="top_headlines"></span>
</div>
<div class="ad_300x250">
			<script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
        <!-- Crashcade 300x250 -->
        <ins class="adsbygoogle"
             style="display:inline-block;width:300px;height:250px"
             data-ad-client="ca-pub-7904820019573435"
             data-ad-slot="2189233018"></ins>
        <script>
        (adsbygoogle = window.adsbygoogle || []).push({});
        </script>
	</div>
<div class="right_stories">
    <h2>Most Recent Stories</h2>
    <span id="recent_stories"> </span>
</div>
<div class="ad_300x250"></div>
<div id="stripmall"></div>
</div>
<div id="tower_column"><div id="floating_ad">
	        <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
        <!-- Crashcade 160x600 -->
        <ins class="adsbygoogle"
             style="display:inline-block;width:160px;height:600px"
             data-ad-client="ca-pub-7904820019573435"
             data-ad-slot="1935746214"></ins>
        <script>
        (adsbygoogle = window.adsbygoogle || []).push({});
        </script>
	</div></div>
</div>


<div class="clear"></div>
<footer id="theme-footer">
    <div id="footer-widget-area">
        <div id="footer-first" class="footer-widget">
            <div id="author-bio-widget-2" class=" Author-Bio">
                <div class="footer-widget-top"><h4>About Us</h4></div>
                <div class="footer-widget-container">			
                    <div class="author-avatar">
                        <img alt="" src="/img/crashcade/favorite.png">
                    </div>
                    <div class="author-description">
                        CrashCade is the hot new Internet sensation. We are dedicated to bringing the best content on the web to our readers, whether it’s a news article, meme, or video and to helping our writers develop a solid readership. Whatever you’re looking for, from the forbidden to the funny, the latest in world news, or a community to share your writing with, let CrashCade be your first stop.			
                    </div>
                    <div class="clear"></div>
                </div>
            </div><!-- .widget /-->
            <div id="author-bio-widget-4" class=" Author-Bio">
                <div class="footer-widget-top"><h4>Contribute</h4></div>
                <div class="footer-widget-container">
                    <div class="author-avatar">
                        <img alt="" src="/img/crashcade/favorite.png">
                    </div>
                    <div class="author-description">
                        To Register as a Contributor, please send an email to info@crashcade.com			
                    </div>
                    <div class="clear"></div>
                </div>
            </div><!-- .widget /-->
        </div>
        <div id="footer-second" class="footer-widget">
            <div id="social-2" class=" social-icons-widget">
                <div class="footer-widget-top"><h4>Social Icons</h4></div>
                <div class="footer-widget-container">    
                    <div class="social-icons icon_32">
                        <a class="ttip" href="/feed" target="_blank" original-title="Rss">
                            <i class="icon-rss"></i>
                        </a>
                        <a class="ttip" href="https://plus.google.com/u/0/b/102311117844022275907/102311117844022275907" target="_blank" original-title="Google+">
                            <i class="icon-gplus"></i>
                        </a>
                        <a class="ttip" href="https://www.facebook.com/CrashCade" target="_blank" original-title="Facebook">
                            <i class="icon-facebook"></i>
                        </a>
                        <a class="ttip" href="https://twitter.com/CrashCadeNews" target="_blank" original-title="Twitter">
                            <i class="icon-twitter"></i>
                        </a>
                        <a class="ttip" href="http://crashcade.blogspot.com/" target="_blank" original-title="Blogger">
                            <i class="icon-blogger"></i>
                        </a>    
                    </div>
                </div>
            </div><!-- .widget /-->
            <div id="widget-feedburner-2" class=" widget-feedburner">
                <div class="footer-widget-top"><h4>FeedBurner Widget</h4></div>
                <div class="footer-widget-container">
                    <div class="widget-feedburner-counter">
                        <p>Subscribe to our email newsletter.</p>
                        <form action="http://feedburner.google.com/fb/a/mailverify" method="post" target="popupwindow" onsubmit="window.open('http://feedburner.google.com/fb/a/mailverify?uri=', 'popupwindow', 'scrollbars=yes,width=550,height=520'); return true">
                            <input class="feedburner-email" type="text" name="email" value="Enter your e-mail address" onfocus="if (this.value == 'Enter your e-mail address') {
                                    this.value = '';
                                }" onblur="if (this.value == '') {
                                    this.value = 'Enter your e-mail address';
                                }">
                            <input type="hidden" value="" name="uri">
                            <input type="hidden" name="loc" value="en_US">			
                            <input class="feedburner-subscribe" type="submit" name="submit" value="Subscribe"> 
                        </form>
                    </div>
                </div>
            </div><!-- .widget /-->
        </div><!-- #second .widget-area -->
        <div id="footer-third" class="footer-widget">
            <div id="facebook-widget-6" class=" facebook-widget">
                <div class="footer-widget-top"><h4>Crashcade on Facebook</h4></div>
                <div class="footer-widget-container">
                    <div class="facebook-box">
                        <iframe src="http://www.facebook.com/plugins/likebox.php?href=https://www.facebook.com/CrashCade&amp;width=300&amp;height=250&amp;colorscheme=dark&amp;show_faces=true&amp;header=false&amp;stream=false&amp;show_border=false" scrolling="no" frameborder="0" style="border:none; overflow:hidden; width:300px; height:250px;" allowtransparency="true"></iframe>
                    </div>
                </div>
            </div><!-- .widget /-->
        </div><!-- #third .widget-area -->
    </div><!-- #footer-widget-area -->
    <div class="clear"></div>
</footer>
<div class="clear"></div>
<div class="footer-bottom container">
    <div class="alignright">
    </div>
    <div class="social-icons icon_16">
        <a class="ttip" href="/feed" target="_blank" original-title="Rss"><i class="tieicon-rss"></i></a><a class="ttip" href="https://plus.google.com/u/0/b/102311117844022275907/102311117844022275907" target="_blank" original-title="Google+"><i class="tieicon-gplus"></i></a><a class="ttip" href="https://www.facebook.com/CrashCade" target="_blank" original-title="Facebook"><i class="tieicon-facebook"></i></a><a class="ttip" href="https://twitter.com/CrashCadeNews" target="_blank" original-title="Twitter"><i class="tieicon-twitter"></i></a><a class="ttip" href="http://crashcade.blogspot.com/" target="_blank" original-title="Blogger"><i class="tieicon-blogger"></i></a>
    </div>

    <div class="alignleft">
        <div class="footer-menu">
            <div id="footer"><a href="/home/about-us/">About Us</a> | <a href="/home/contact/">Contact</a> | <a href="/home/contributors/">Contributors</a> | <a href="/home/copyright-notice/">Copyright Notice</a> | <a href="/home/subscribe/">Subscribe</a> | <a href="/widgets/">Widgets</a></div>
            <div>Portions copyright © 2014 CrashCade, All Rights Reserved.</div>
        </div>
    </div>
    <div class="clear"></div>
</div><!-- .Container -->
</div>
<div style="display: none;"><p><a href="/notyet/notyet.html" id="lightbox" name="lightbox">Register</a></p></div>
    <div style="display: none;"><p><a href="/contribute/newsletter/subscribe.html" id="lightbox_newsletter" name="lightbox_newsletter">Newsletter</a></p></div>
    <div style="display: none;"><a id="lightbox_email_send" href="/bottom_send_mail/email.php" title="Email this story">Email this story</a></div>
    <div style="display: none;"><a id="lightbox_email" href="/bottom_float/email.html" title="Email this story">Email this story</a></div>
    <div id="social_bottom_float">
        <div id="sbf_share_this_story">
            <div class="bf_title">Share This Story:</div>
            <div class="bf_tools">
				                <div id="bf_social_print"><img id="bf_social_print_icon" class="bf_icon" width="20" height="20" src="/img/print.png" alt="Print this story" /></div>
                <div id="bf_social_email"><img id="bf_social_email_icon" class="bf_icon" width="20" height="20" src="/img/mail.png" alt="Email this story" /></div>
				<div id="bf_social_fbshare"><div class="fb-share-button" data-layout="button_count" ></div></div>
				<div id="bf_social_twitter">
					<a href="https://twitter.com/share" class="twitter-share-button" data-url="" data-text="MOUNTAIN VIEW, CA–(Marketwired – October 06, 2014) – VIVUS, Inc. (NASDAQ: VVUS) today..." data-via="CrashCadeNews" data-counturl="http://crashcade.com/press-release/2014/10/newly-published-data-highlight-the-effects-of-weight-loss-with-qsymia-in-type-2-diabetes-386.html">Tweet</a>
					<script>!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+'://platform.twitter.com/widgets.js';fjs.parentNode.insertBefore(js,fjs);}}(document, 'script', 'twitter-wjs');</script>
				</div>
                <div id="bf_social_digg"><a id="digg_link" title="Share on Digg" target="_blank" href="//digg.com/submit?url=&title=Newly+Published+Data+Highlight+the+Effects+of+Weight+Loss+With+Qsymia+in+Type+2+Diabetes&bodytext=MOUNTAIN+VIEW%2C+CA%E2%80%93%28Marketwired+%E2%80%93+October+06%2C+2014%29+%E2%80%93+VIVUS%2C+Inc.+%28NASDAQ%3A+VVUS%29+today+announced+the+publication+of+a+paper+examining+study+results..."><img class="bf_icon" width="20" height="20" src="/img/digg.png" alt="Digg" /></a></div>
                <div id="bf_social_reddit"><a id="reddit_link" title="Share on Reddit" target="_blank" href="//www.reddit.com/submit?url=&title=Newly+Published+Data+Highlight+the+Effects+of+Weight+Loss+With+Qsymia+in+Type+2+Diabetes"><img class="bf_icon" width="20" height="20" src="/img/reddit.png" alt="Reddit" /></a></div>
                <div id="bf_social_stumbleupon"><a id="stumbleupon_link" title="Share on StumbleUpon" target="_blank" href="//www.stumbleupon.com/submit?url=http%3A%2F%2Fcrashcade.com%2Fpress-release%2F2014%2F10%2Fnewly-published-data-highlight-the-effects-of-weight-loss-with-qsymia-in-type-2-diabetes-386.html&title=Newly+Published+Data+Highlight+the+Effects+of+Weight+Loss+With+Qsymia+in+Type+2+Diabetes&newcomment=MOUNTAIN+VIEW%2C+CA%E2%80%93%28Marketwired+%E2%80%93+October+06%2C+2014%29+%E2%80%93+VIVUS%2C+Inc.+%28NASDAQ%3A+VVUS%29+today+announced+the+publication+of+a+paper+examining+study+results..."><img class="bf_icon" width="20" height="20" src="/img/stumbleupon.png" alt="StumbleUpon" /></a></div>
                <div id="bf_social_tumblr"><a id="tumblr_link" title="Share on Tumblr" target="_blank" href="//www.tumblr.com/share/link?url=&name=Newly+Published+Data+Highlight+the+Effects+of+Weight+Loss+With+Qsymia+in+Type+2+Diabetes&description=MOUNTAIN+VIEW%2C+CA%E2%80%93%28Marketwired+%E2%80%93+October+06%2C+2014%29+%E2%80%93+VIVUS%2C+Inc.+%28NASDAQ%3A+VVUS%29+today+announced+the+publication+of+a+paper+examining+study+results..."><img class="bf_icon" width="20" height="20" src="/img/tumblr0.png" alt="Share on Tumblr" /></a></div>
                <div id="bf_social_send_special_email">
                    <span style="margin-left: 10px;">GET ALERTS:</span>
                    <input type="text" class="share_boxes_input_edit" value="Enter email" onfocus="this.value = ''" id="subscribe_user_email">
                    <input type="button" class="mail-sign-up" onclick="QuickSubscribeUser();" value="Sign Up" />
                    <img id="loading" style="display: none;" src="/img/wait.gif" />
                </div>
            </div>
        </div>
    </div>
    <div class="tooltipContent" id="likeContributorMessage"></div>
    <div class="tooltipContent" id="likeStoryMessage"></div>
    <div class="tooltipContent" id="authorMessage"></div>
    <div class="tooltipContent" id="subscribenewsletterMessage"></div>
    <div style="display:none; clear: both">
        <div id="ban_reason">
            <p id="ban_reason_message">If you really want to ban this commenter, please write down the reason:</p>
            <textarea id="ban_reason_content" style="height: 200px; width: 550px" cols="200" rows="25"></textarea>
        </div>
        <div id="bin_alert"></div>
        <div id="turn_off_float_story">If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.</div>
    </div>
    <script type="text/javascript">function runCutTextScript(){  }</script><script type="text/javascript">
    var _sf_async_config = {uid: 7117, domain: "crashcade.com"};
    (function() {
        function loadChartbeat() {
            _sf_async_config.path = window.location.pathname;
            _sf_async_config.sections = 'Single Story,English Story,Press Release';
            _sf_async_config.authors = 'CDN';
            _sf_endpt = (new Date()).getTime();
            var e = document.createElement('script');
            e.setAttribute('language', 'javascript');
            e.setAttribute('type', 'text/javascript');
            e.setAttribute('src', 'http://static.chartbeat.com/js/chartbeat.js');
            document.body.appendChild(e);
        }
        var oldonload = window.onload;
        window.onload = (typeof window.onload != 'function') ?
            loadChartbeat : function() {
                oldonload();
                loadChartbeat();
            };
    })();
</script>
</div>
</body>
</html>